Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional ...
Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback